Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Any weapons-grade nuclear material must have a critical mass that is small enough to justify its use in a weapon. The critical mass for any material is the smallest amount needed for a sustained nuclear chain reaction. Moreover, different isotopes have different critical masses, and the critical mass for many radioactive isotopes is infinite, because the mode of decay of one atom cannot induce similar decay of more than one neighboring atom. For example, the critical mass of uranium-238 is infinite, while the critical masses of uranium-233 and uranium-235 are finite. The critical mass for any isotope is influenced by any impurities and the physical shape of the material. The shape with minimal critical mass and the smallest physical dimensions is a sphere. Bare-sphere critical masses at normal density of some actinides are listed in the accompanying table. Most information on bare sphere masses is classified, but some documents have been declassified.
Epalrestat is a carboxylic acid derivative and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in that it is a drug that contains a rhodanine group. Aldose reductase is the key enzyme in the polyol pathway whose enhanced activity is the basis of diabetic neuropathy. Aldose reductase inhibitors (ARI) target this enzyme. Out of the many ARIs developed, ranirestat and fidarestat are in the trial stage. Others have been discarded due to unacceptable adverse effects or weak efficacy. Epalrestat is the only ARI commercially available. It is easily absorbed into the neural tissue and inhibits the enzyme with minimum side effects.
The Forestry Corps can trace its lineage to the Armed Forest Protection Battalions (Chinese: 武装护林大队); There were a total of four battalions; Each of the Hejiang, Songjiang, Longjiang and Jilin provinces consisted of one Armed Forest Protection Battalion. Founded on 25 August 1948, these units were created to conduct counterinsurgency operations against Japanese/Collaborator holdouts (This role was also later expanded to KMT holdouts after the Chinese Civil War), bandits and triads in Northeast China, which would often raid local villages and commit acts of arson, causing wildfires. At the time of establishment, each had 960 soldiers (3840 soldiers, all battalions combined). The Armed Forest Protection Battalions would often disguise themselves as hunters during recon, and used Cavalry tactics. By 16 October 1950, each battalion had 1600 soldiers (6400 Soldiers total). According to archives, by 1952, the Armed Forest Protection Battalions had killed a total of 6 KMT and American spies along with capturing a total of 46 spies, 34 triad members and 71 illegal migrants along with 68 firearms, multiple tens of thousand rounds of ammunition, multiple kilograms of drugs and prevented a total of 7 vandalism incidents. On 11 May 1953, the Armed Forest Protection Battalions were transferred to the People's Economic Police and renamed to the Forest Protection Police (Chinese: 护林警察队). Its task was to patrol forests, prevent illegal entry of protected areas and to serve as lookouts for forest fires.
Inspections and audits like also be conducted on a regular basis to assess hazards due to chemical handling and storage, electrical equipment, biohazards, hazardous waste management, chemical waste, housekeeping and emergency preparedness, radiation safety, ventilation as well as respiratory testing and indoor air quality. An important element of such audits is the review of regulatory compliance and the training of individuals who have access to or work in the laboratory. Training is critical to the ongoing safe operation of the laboratory facility. Educators, staff and management must be engaged in working to reduce the likelihood of accidents, injuries and potential litigation. Efforts are often made to ensure laboratory safety videos are both relevant and engaging.
Russell demonstrated that alkaline vents create an abiogenic proton motive force chemiosmotic gradient, ideal for abiogenesis. Their microscopic compartments "provide a natural means of concentrating organic molecules," composed of iron-sulfur minerals such as mackinawite, endowed these mineral cells with the catalytic properties envisaged by Günter Wächtershäuser. This movement of ions across the membrane depends on two factors:
Sources: en.wikipedia.org
On the other hand, by inhibiting miR-33 function, the level of ABCA1 is increased, which increases the cholesterol efflux to apoA-1. Suppression of miR-33 will lead to less cellular cholesterol and higher plasma HDL level through the regulation of ABCA1 expression.
Traditionally in composite science a strong interface between the matrix and filler is required to achieve favorable mechanical properties. If this is not the case, the phases tend to separate along the weak interface and makes for very poor mechanical properties. In a MCC composite however this is not the case, if the interaction between the filler and matrix is stronger than the filler-filler interaction the mechanical strength of the composite is noticeably decreased. Difficulties in natural fiber nanocomposites arise from dispersity and the tendency small fibers to aggregate in the matrix. Because of the high surface area to volume ratio the fibers have a tendency to aggregate, more so than in micro-scale composites. Additionally secondary processing of collagen sources to obtain sufficient purity collagen micro fibrils adds a degree of cost and challenge to creating a load bearing cellulose or other filler based nanocomposite.
Compounds with krypton bonded to atoms other than fluorine have also been discovered. There are also unverified reports of a barium salt of a krypton oxoacid. ArKr+ and KrH+ polyatomic ions have been investigated and there is evidence for KrXe or KrXe+. The reaction of KrF2 with B(OTeF5)3 produces an unstable compound, Kr(OTeF5)2, that contains a krypton-oxygen bond. A krypton-nitrogen bond is found in the cation [HC≡N−Kr−F]+, produced by the reaction of KrF2 with [HC≡NH]+[AsF6]−] below 223 K (−50 °C). HKrCN and HKrC≡CH (krypton hydride-cyanide and hydrokryptoacetylene) were reported to be stable up to 40 K (−233.2 °C). Krypton hydride (Kr(H2)4) crystals can be grown at pressures above 5 GPa. They have a face-centered cubic structure where krypton octahedra are surrounded by randomly oriented hydrogen molecules. The kryptonium ion, KrH+, is an onium ion, consisting of protonated krypton. Kryptonium is known in dilute gas phase. Although salts of the fluorokryptonium ion, KrF+, are known to exist, the existence of the kryptonium salts have not been proven. In 1989, Bergman, Moore, Pimentel and coworkers photolyzed a rhodium(I) complex, Cp*Rh(CO)2 (Cp* = pentamethylcyclopentadienyl), using a pulsed XeCl laser (308 nm) in pressurized liquid Kr as a solvent at a temperature between −80 and −120 °C (193 and 153 K) and observed the formation of Cp*Rh(CO)(Kr), which was identified by infrared spectroscopy by its metal–carbonyl stretch at 1946 cm−1. This species decayed with a rate constant of k = 5 × 103 s−1 at −80 °C (193 K).
Rattlesnake fangs are connected by venom ducts to large venom glands near the outer edge of the upper jaw, towards the rear of the head. When the rattlesnake bites, muscles on the sides of the venom glands contract to squeeze the venom through the ducts and into the fangs. When the fangs are not in use, they remain folded against the palate. Rattlesnakes are born with fully functioning fangs and venom, and are capable of killing prey at birth. Adult rattlesnakes shed their fangs every 6–10 weeks. At least three pairs of replacement fangs lie behind the functional pair.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.